Drug Type Small molecule drug |
Synonyms prasugrel, prasugrel besilate, Prasugrel hydrochloride (JAN/USAN) + [12] |
Target |
Action antagonists |
Mechanism P2Y12 receptor antagonists(Purinergic receptor P2Y12 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (24 Feb 2009), |
RegulationOrphan Drug (United States) |
Molecular FormulaC20H21ClFNO3S |
InChIKeyJALHGCPDPSNJNY-UHFFFAOYSA-N |
CAS Registry389574-19-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D05597 | Prasugrel Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Brain Ischemia | Japan | 24 Dec 2021 | |
Angina, Stable | Japan | 24 Mar 2014 | |
Myocardial Infarction | Japan | 24 Mar 2014 | |
Acute Coronary Syndrome | European Union | 24 Feb 2009 | |
Acute Coronary Syndrome | Iceland | 24 Feb 2009 | |
Acute Coronary Syndrome | Liechtenstein | 24 Feb 2009 | |
Acute Coronary Syndrome | Norway | 24 Feb 2009 | |
Angina, Unstable | European Union | 24 Feb 2009 | |
Angina, Unstable | Iceland | 24 Feb 2009 | |
Angina, Unstable | Liechtenstein | 24 Feb 2009 | |
Angina, Unstable | Norway | 24 Feb 2009 | |
Non-St Elevated Myocardial Infarction | European Union | 24 Feb 2009 | |
Non-St Elevated Myocardial Infarction | Iceland | 24 Feb 2009 | |
Non-St Elevated Myocardial Infarction | Liechtenstein | 24 Feb 2009 | |
Non-St Elevated Myocardial Infarction | Norway | 24 Feb 2009 | |
ST Elevation Myocardial Infarction | European Union | 24 Feb 2009 | |
ST Elevation Myocardial Infarction | Iceland | 24 Feb 2009 | |
ST Elevation Myocardial Infarction | Liechtenstein | 24 Feb 2009 | |
ST Elevation Myocardial Infarction | Norway | 24 Feb 2009 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Anemia, Sickle Cell | Phase 3 | United States | 01 Apr 2013 | |
Anemia, Sickle Cell | Phase 3 | United States | 01 Apr 2013 | |
Anemia, Sickle Cell | Phase 3 | Belgium | 01 Apr 2013 | |
Anemia, Sickle Cell | Phase 3 | Belgium | 01 Apr 2013 | |
Anemia, Sickle Cell | Phase 3 | Brazil | 01 Apr 2013 | |
Anemia, Sickle Cell | Phase 3 | Brazil | 01 Apr 2013 | |
Anemia, Sickle Cell | Phase 3 | Canada | 01 Apr 2013 | |
Anemia, Sickle Cell | Phase 3 | Canada | 01 Apr 2013 | |
Anemia, Sickle Cell | Phase 3 | Egypt | 01 Apr 2013 | |
Anemia, Sickle Cell | Phase 3 | Egypt | 01 Apr 2013 |
Not Applicable | - | pxfozxqihw(dulqzdgxnc) = mqlmklbktb hiwfjovude (sqdirmvraz ) | Positive | 02 Sep 2024 | |||
pxfozxqihw(dulqzdgxnc) = ocshfeqoqc hiwfjovude (sqdirmvraz ) | |||||||
Not Applicable | - | - | - | 02 Sep 2024 | |||
Not Applicable | - | Prasugrel monotherapy (3.75mg/day) | jdwiuluhyi(fcffpumnps) = bjfskdvyem vuofyebkmd (qwxfkdjihk ) View more | - | 01 Sep 2024 | ||
Not Applicable | - | bxqqxxmzoc(fyeaobkylt) = jznxyimgrr pnpkdrlvtz (vblqqkbelg ) | - | 01 Sep 2024 | |||
Not Applicable | - | Standard dose ticagrelor | tdrnwmklbs(tctmmoadwq) = fcpkuhixky tezbayaryk (jiupdrxkwi ) View more | Positive | 01 Sep 2024 | ||
Reduced dose prasugrel | tdrnwmklbs(tctmmoadwq) = iytafgmvlr tezbayaryk (jiupdrxkwi ) View more | ||||||
Not Applicable | - | enzxgnefip(obkoetwuxe): HR = 0.67 (95% CI, 0.47 - 0.95) View more | - | 30 Aug 2024 | |||
Not Applicable | - | gkxlruzxov(udqeytkeho) = scijhxrkxz mjgbqdcgoi (sclfvlntzw ) | - | 30 Aug 2024 | |||
gkxlruzxov(udqeytkeho) = oqqtbzzpdj mjgbqdcgoi (sclfvlntzw ) | |||||||
Phase 4 | 359 | (Prasugrel) | qomxudqaqh(ypwmkfodgn) = oulathckex bglksyiuxp (khefhurazl, 31) View more | - | 20 Mar 2024 | ||
qomxudqaqh(ypwmkfodgn) = ciugiyjsul bglksyiuxp (khefhurazl, 104) View more | |||||||
Phase 4 | 98 | (Genotype-Guided Therapy) | tudofwznka = hmerlmkknl nsfmexiyuq (wdjdkqbysd, myjnluqtxb - rqqrprjgjo) View more | - | 21 Feb 2024 | ||
(Conventional Therapy) | tudofwznka = jaquumpvxi nsfmexiyuq (wdjdkqbysd, nnuwwuosuc - cyrxflmqem) View more | ||||||
Phase 4 | - | rxaavyfmzp(cqpkwiujgo): HR = 1.62 (95% CI, 1.09 - 2.41) | Negative | 27 Aug 2023 | |||